- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05828966
HUMAN CHORIONIC GONADOTROPIN (HcG) VS MAGNESIUM SULPHATE (MgSo4) AS A TOCOLYTIC AGENT- A RANDOMIZED CONTROLLED TRIAL
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Preterm labor is defined as regular contractions of the uterus resulting in changes in the cervix (effacement and dilatation) that start before 37 weeks of pregnancy. (1) Although preterm labor constitutes only 10% of total labors, yet 70% of infant's mortality is related to prematurity. It is therefore one of the international indices in assessment of health condition worldwide. Factors that increase the risk of preterm birth include history of previous preterm birth, short cervix, short time between pregnancies, teenage pregnancy, history of certain types of surgery on the uterus or cervix, certain pregnancy complications, such as multiple pregnancy and vaginal bleeding and lifestyle factors such as low pre-pregnancy weight, smoking during pregnancy, and substance abuse during pregnancy.
Preterm labor can be diagnosed clinically only when changes in the cervix are found after pelvic examination along with contractions also may be monitored. A transvaginal ultrasound exam may be done to measure the length of your cervix. Tocolytics are drugs used to delay delivery for a short time (up to 48 hours). They may allow time for corticosteroids or magnesium sulfate to be given or for you to be transferred to a hospital that offers specialized care for preterm infants. (1,2) Tocolytic agents are β- HCG, MgSO4, nifedipine, β-agonists(salbutamol) and atosiban. Use of salbutamol is of limited use because of many cardiovascular complications i.e., ventricular arrythmia, hypertension and hyperglycemia while atosiban is expensive and not available in Pakistan.
Human Chorionic Gonadotropin (H.C.G.) is a heterodimeric glycoprotein produced primarily in the placenta and has multiple endocrines, paracrine and immunoregulatory actions. (3) The importance of H.C.G. in maintenance of early pregnancy has been widely accepted, reports have highlighted a potential role of H.C.G. in maintaining uterine quiescence in the third trimester. H.C.G. exerts a potent concentration dependent inhibitory effect on human myometrial contractions. (4) Recent data suggests that H.C.G. might have a role as an endogenous tocolytic agent in normal pregnancy. A significant decrease in serum H.C.G. level was found 2-3 weeks before the spontaneous onset of labour. This might contribute to increasing the contractility in the uterine muscle and gradually initiating the onset of labour. (5) Following I.M. injection, peak concentration of H.C.G. occurs about 6 hrs after a dose. It is distributed primarily to gonads. Blood concentration declines in a biphasic manner, with a half-life between about 6 and 11 hrs and 23 to 38 hrs respectively. About 10 to 12% of an IM dose is excreted in urine within 24 hours. (6)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Islamabad, Pakistan, 44000
- Mother and Child Care Hospital, Shaheed Zulfiqar Ali Bhutto Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 4 uterine contractions per 20 min or 8 contractions per hour
- single live fetus
- Pregnancy less than 37 weeks
- Intact Membranes,
- Dilatation less than 3cm and effacement less than 80%.
Exclusion Criteria:
- Cervical Dilatation more than 4 cm
- Abnormal vaginal bleeding
- Premature Rupture of membranes
- Cardiopulmonary compromised
- Fetal and Uterine anomalies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: HUMAN CHORIONIC GONADOTROPIN (HCG) Group
H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
Half hourly assessment of uterine contractions, maternal vital signs, fetal heart rate monitoring will be done.
|
H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
|
|
Active Comparator: Magnesium Sulphate(MgSO4) Group
4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
|
4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tocolysis
Time Frame: 48 hours
|
Tocolysis will be considered successful when contractions ceased and delivery will be delayed by 48 hrs giving time to the administered corticosteroids to accelerate fetal lung maturation
|
48 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pregnancy Complications
- Obstetric Labor Complications
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Obstetric Labor, Premature
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Chorionic Gonadotropin
- Magnesium Sulfate
Other Study ID Numbers
- 001 (Buy Pharma Ecza Deposu San. Tic. Ltd.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Labor
-
University Hospital, Strasbourg, FranceRecruitingPreterm Delivery | Threatened Preterm LaborFrance
-
Ain Shams UniversityRecruitingPreterm Labor With Preterm DeliveryEgypt
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Shiraz University of Medical SciencesCompletedManaging Preterm Labor
-
Ain Shams Maternity HospitalCompletedThreatened Preterm LaborEgypt
-
Konya Meram State HospitalRecruitingPregnancy Preterm | Preterm Labor Without DeliveryTurkey
-
Hospital Clinico Universitario de SantiagoFundación Ramón DomínguezWithdrawnThreatened Preterm Labor
-
PreTeL, IncUniversity of RochesterCompletedPreterm Labor | Pregnancy Preterm | Labor; IrregularUnited States
-
Istanbul University - Cerrahpasa (IUC)Kilis 7 Aralik UniversityCompletedPreterm Labor | Preterm Labor with Preterm Delivery in Third Trimester | Preterm Spontaneous Labor with Preterm DeliveryTurkey
-
Assiut UniversityUnknown
Clinical Trials on human chorionic gonadotropin (hCG)
-
Mansoura UniversityUnknownInfertility | Invitro FertilizationEgypt
-
Michigan State UniversityCompleted
-
Beijing Children's HospitalUnknownKallmann Syndrome | Hypogonadotropic HypogonadismChina
-
The Fourth Affiliated Hospital of Zhejiang University...Not yet recruitingPremature Ovarian Insufficiency
-
Martin Blomberg JensenCompleted
-
Azienda USL ModenaCompletedHuman Chorionic Gonadotropin Stimulation Effects on Steroidogenesis in Men With Klinefelter SyndromeKlinefelter Syndrome | Steroidogenesis | Human Chorionic Gonadotropin (hCG) StimulationItaly
-
Masonic Cancer Center, University of MinnesotaCompletedGraft vs Host DiseaseUnited States
-
Universitair Ziekenhuis BrusselHuman Reproduction & Genetics FoundationUnknownPregnancy Outcome | Endometrial ThicknessGreece
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingAcquired Hypogonadotropic HypogonadismItaly
-
Tongji HospitalRecruitingInfertility | Kallmann Syndrome | Isolated Hypogonadotropic HypogonadismChina